OINDPnews

Lovaltech gets go-ahead for MUCOBOOST Phase 1 trial of LVT-001 intranasal vaccine against COVID-19

French biotech Lovaltech announced that the Agence nationale de sécurité du médicament (ANSM) and the Comité de Protection des Personnes (CPP) have authorized the company's planned MUCOBOOST Phase 1 trial of LVT-001 nasal vaccine against COVID-19, and the trial is expected to start by the end of … [Read More...] about Lovaltech gets go-ahead for MUCOBOOST Phase 1 trial of LVT-001 intranasal vaccine against COVID-19

Orbia announces appointments in its MDI propellants business

Orbia Fluor & Energy Materials (formerly Koura) has announced the appointments of a new General Manager, Global Commercial Director, UK Operations Director, and Technical Manager for its Pharma Business Unit, which includes Zephex brand MDI propellants, including its HFA 152a LGWP propellant. … [Read More...] about Orbia announces appointments in its MDI propellants business

Health Canada approves Hikma’s Kloxxado naloxone nasal spray, which will be marketed in Canada by Emergent BioSolutions

According to Emergent BioSolutions, Health Canada has approved Hikma Pharmaceuticals' Kloxxado naloxone nasal spray 8 mg for the treatment of opioid overdose. In January 2025, Emergent announced that it was acquiring US and Canadian rights to Kloxxado, which has been approved in the US since 2021. … [Read More...] about Health Canada approves Hikma’s Kloxxado naloxone nasal spray, which will be marketed in Canada by Emergent BioSolutions

Paratek to acquire Optinose

US-based Paratek Pharmaceuticals will acquire all outstanding shares of intranasal drug developer Optinose in a deal worth up to $330 million, the companies said. According to the announcement, both companies' boards have approved the deal, which could close by mid-2025. Paratek will pay $9 per … [Read More...] about Paratek to acquire Optinose

Cyrano licenses Resyca’s soft mist technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral loss of smell

Cyrano Therapeutics has acquired an exclusive license to use Resyca’s soft mist nasal spray technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral hyposmia. According to the announcement, the Phase 2 FLAVOR study of CYR-064 that was initiated in 2023 has been … [Read More...] about Cyrano licenses Resyca’s soft mist technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral loss of smell

More news . . .

DDL 2024 in review

DDL 2024 to celebrate 35 years as a leading OINDP conference

A Q&A with Copley’s Clair Brooks on alternative BE approaches in new FDA guidance

Latest news

Lovaltech gets go-ahead for MUCOBOOST Phase 1 trial of LVT-001 intranasal vaccine against COVID-19

Orbia announces appointments in its MDI propellants business

Health Canada approves Hikma’s Kloxxado naloxone nasal spray, which will be marketed in Canada by Emergent BioSolutions

Paratek to acquire Optinose

Cyrano licenses Resyca’s soft mist technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral loss of smell

Other recent news